Publication details

Munro Partners

November 12, 2020

Area of Interest: Innovative Health


Munro Partners

Munro Partners' Chief Investment Officer Nick Griffin delves into our current largest Area of Interest - Innovative Health. He discusses the tailwinds for Innovative Health in general and then identifies the ramifications of COVID on testing and vaccines for three companies.

Recorded 15 October 2020.

Disclaimer: Munro Partners mentions particular investments that the Fund may or does hold. This is not a recommendation. The Fund may not hold the investment at the time this video is published and/or when it is viewed. It is provided for indicative purposes only. The information contained in this video presentation reflects, as of the date of publication, the views of Munro Partners and sources believed by Munro Partners to be reliable. There can be no guarantee that any projection, forecast or opinion in these materials will be realised. The views expressed in this video may change at any time subsequent to the date of issue. The information contained in this presentation is general in nature and should not be relied upon. Before making any investment or planning decisions, you should consult a licensed professional who can advise you whether your decision is appropriate for you. While this information is provided in good faith and is derived from sources believed to be accurate and reliable at the time of publication, Munro makes no warranty as to the accuracy or reliability of the information.

GSFM Responsible Entity Services Limited ABN 48 129 256 104 AFSL 321517 (GSFM Responsible Entity Services) is the responsible entity of the Munro Global Growth Fund ARSN 612 854 547 APIR MUA0002AU (MGGF) and the Munro Concentrated Global Growth Fund ARSN 630 173 189 APIR GSF9808AU (MCGGF), together “Funds”, and is the issuer of this information. This information has been prepared without taking account of the objectives, financial situation or needs of individuals. Before making an investment decision in relation to the Funds, investors should consider the appropriateness of this information, having regard to their own objectives, financial situation and needs and read and consider the product disclosure statement for the Funds the MGGF dated 25 March 2019, and MCGGF dated 31 October 2019 and the Additional Information to the PDS, both of which may be obtained from or performance information given in this document is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. None of GSFM Responsible Entity Services, Munro Partners its related bodies or associates nor any other person guarantees the repayment of capital or the performance of the Fund or any particular returns from the Fund. No representation or warranty is made concerning the accuracy of any data contained in this document. The Top 5 Holdings depict end of quarter figures and may have changed materially from holdings during the quarter or not disclosed due to confidentiality reasons. Numbers may not sum due to rounding or compounding returns.

Related articles